First In-human Study Update: Study Open for Enrolment
Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients
Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients
Early detection is critical to improving cancer survival rates. Too often, the limitations of today’s medical imaging technologies result in cancer being detected at late
Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after costs) in
Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the Company moves into its
Imagion Biosystems is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense® HER2 Phase I study
Earlier this year Imagion Biosystems CEO Bob Proulx was invited to be a guest and record an episode of the Biotech2050 podcast. The COVID-19 pandemic delayed
Imagion Biosystems has announced Appendix 4D and Half Year Results H1 2020. These are the highlights: Significant advancements towards initiating first-in-human study, on track to
Imagion Biosystems Limited announce that it has received $1.29m for the exercise of unlisted options issued under the terms of the 2018 Rights Issue outlined
Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense® product for
Imagion Biosystems Limited gives notice that, on 4 August 2020 the Company issued 112,111,111 fully paid ordinary shares (Shares) as well as 6,500,000 Listed Options
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance